The comparative effect and safety of 2 IU compared with 4 IU/m2/day of recombinant human growth hormone (rhGH) was studied in 38 growth hormone deficient children regarding the impact of several factors on short term (one year) and long term (three year) growth response.
In 21 newly diagnosed patients, three years of rhGH treatment resulted in a significant increase of height velocity SD score, height SD score, and predicted adult height SD score, irrespective of rhGH dose. In 17 transfer patients (previously treated with 12 IU rhGH/m2/week) 4 IU/m2/day resulted in a significantly higher height velocity SD score and height SD score for chronological age than 2 IU/m2/day, while more of them reached their target range or showed a substantial height SD score increment. Height SD score for bone age and predicted adult height SD score only increased significantly with 4 IU rhGH.
After one year of rhGH treatment, new patients showed significant negative correlation between A height SD score with age and baseline insulin-like growth factor I (IGF-I) SD score, and positive correlation with rhGH dose. After three years of treatment, A height SD score for chronological age was significantly, negatively correlated with age and baseline 'corrected' height SD score (height SD score for chronological age minus target height SD score). There was no significant correlation with rhGH dose. Prolonged treatment with either dose had no adverse effect on IGF-I concentrations, carbohydrate or lipid metabolism.
As early age and divergence between height SD score and target height SD score seem more important for growth response [12] [13] [14] [15] [16] [17] [18] The aim of growth hormone treatment for children with growth hormone deficiency is to induce normal growth during the growth phase and thereby achieve a final adult height in conformity with the individual target height or the adult height of the general population. The Age in years 14 16 18 20 Transfer patients
.. Table 3 Results ofstepwise multiple regression analysis of increment in height SD score for chronological age after one year and after three years of rhGH treatment in new patients BMI SD score and sitting height/subischial leg length ratio SD score had not changed significantly after three years of rhGH treatment irrespective of dose. At the start and after three years of rhGH, the mean (SD) sitting height/subischial leg length ratio SD score was 0-71 (1-10) and 1-06 (0-93) for subset A and 0-40 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) and 0-14 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) for subset B. Table 3 gives the results of the stepwise multiple regression analysis of A height SD score for chronological age after one and after three years of rhGH treatment. It appeared that an older age and a higher IGF-I value at the start of rhGH treatment had a significantly negative effect on the short term growth response, while female sex and the higher rhGH dose (4 v 2 IU) had a significantly Apo-Al (mg/100 ml) positive effect. Age and corrected height SD score for chronological age at the start of rhGH treatment had a significantly negative effect on the long term growth response. Dose of rhGH did not reach the conventional level of statistical significance (p=0 08).
Transfer patients During the first two study years, height velocity SD score increased significantly only for subset B on 4 IU/m2/day. In all three study years height velocity SD score was significantly higher for patients receiving 4 IU than for those on 2 IU/m2/day. Height velocity only increased significantly in subset B patients during the first study year, and likewise during year 2 once pubertal patients were excluded. Height SD score for chronological age had increased significantly compared with prestudy values after three years of study with either rhGH dose, but significantly more so with the higher dose.
Bone age advance during the three years of study was similar for both subsets, irrespective of inclusion of pubertal patients. Height SD score for bone age and predicted adult height SD score increased significantly with 4 IU/m2/day only.
The figure shows corrected height SD score for chronological age for all 17 transfer patients. Significantly more patients of subset B (eight out of eight) than of subset A (five out of nine) had attained a height SD score for chronological age above the lower limit of the target range at the end of the third study year, or the increase in height SD score for chronological age during year 3 surpassed 0-25 SD scores, or both (p=0 03). For two subset B patients, height SD score for chronological age surpassed target height SD score with more than 2 SD scores. During the three years of study, the mean (SD) corrected height SD score for chronological age of subset A patients, on 2 IU/m2/day, increased from -1-99 (0-8 1) to -1 11 (1.2 1), while subset B on 4 IU showed a significantly greater increase (p<0 05) from -2-10 (1.77) to -0-17 (2.08).
BMI SD score did not change significantly irrespective of rhGH dose. After three years of study, the mean (SD) sitting height/subischial leg length ratio SD score had decreased significantly with either dose, from 0-69 (1 11) to 0-0 (1-38) with 2 IU and from 1-05
(1-56) to 0-01 ( 1 13) Plasma IGF-I Concentrations of IGF-I and IGF-I SD score of new patients increased significantly during three years of rhGH treatment. In the first two years the increment was higher with 4 than with 2 IU/m2/day, but this difference was not statistically significant. After one year of treatment, six patients (one of subset A and five of subset B) had an IGF-I SD score higher than two, after three years only one patient of subset B had an IGF-I SD score of more than 2 SD scores (2.6 SD scores). The mean (SD) IGF-I SD score after three years of rhGH treatment amounted to -0 01 (1 36) for subset A on 2 IU, and 0 79 (1-82) for subset B on 4 IU/m2/day.
Carbohydrate and lipid metabolism During the 3 years of study, mean (SD) concentrations of HbA1 decreased in all patients, irrespective of rhGH dose, from 6-7 (1-4) to 5-6 (0-6)% in the new patients and from 6-6 (0 5) to 5 9 (0.6)% in the transfer patients. Table 4 shows concentrations of HbAl and blood lipids before and after three years of rhGH treatment in the new growth hormone deficient patients compared with controls.
Thyroidfunction
Before the start of the study two new and 10 transfer patients received thyroid medication. In the course of the study, two additional new patients (one of either subsets) and one transfer patient (subset B) required thyroid treatment, because of subnormal thyroxine with low TSH concentrations. There were no clinical signs of hypothyroidism.
Antigrowth hormone antibodies After three years of study, none of either new or transfer patients had developed antigrowth hormone antibodies. Four transfer patients, previously treated with methionyl rhGH, had antigrowth hormone antibodies at the start of the study, but these disappeared after 3-18 months of treatment with authentic rhGH.
Other haematological and biochemical variables Slight, but clinically insignificant changes occurred in both new and transfer patients regarding haemoglobin, packed cell volume, white cell count and differentiation, as well as platelet count. All values remained within normal limits during three years of study.
Discussion
The height velocity (expressed as SD score) of all new growth hormone deficient patients remained above pretreatment values during three years of rhGH treatment. Evaluation at the end of the first study year showed that 4 IU had a significantly stronger effect on growth than 2 IU/m2/day after correction for the severity of growth hormone deficiency.4
However, this difference disappeared during prolonged treatment. We found comparable results for the increment in height SD score for chronological age during rhGH treatment, which we considered a more appropriate measure of short term (one year) and long term (three year) growth response. While the higher rhGH dose had a significantly greater effect on the short term growth response, this effect faded during three years of rhGH treatment. In the multiple regression analysis with A height SD score for chronological age after 3 years as dependent variable, the correlation with the rhGH dose showed a trend towards significance (p=008) with a regression coefficient of 0 33 (95% confidence interval -0 03 to 0-68), suggesting that after three years of rhGH treatment, height SD scores of patients on 4 IU might increase with approximately 0-66 SD scores more than that of patients receiving 2 IU/m2/day.
Our study clearly shows that age at start of treatment is paramount importance for both short term and long term growth response. The younger the child at the start of rhGH treatment, the better the gain in height. Also, the shorter the child in relation to target height at the start of treatment, the better the growth response, implying that both pretreatment height and target height are of influence.
These observations confirm earlier reports.1317
However, it should be emphasised that all these studies are retrospective evaluations of growth hormone treatment for growth hormone deficiency with variable frequencies of growth hormone administration and/or lower growth hormone dosages than in our study. One of the reports concerns a recent analysis of growth hormone treatment of a large group of growth hormone deficient patients. 16 The authors observed that the magnitude of the first year growth response was inversely correlated with chronological age and height SD score at the start of treatment, but was positively correlated with the growth hormone dose, the frequency of gowth hormone injections per week, and midparental height.
We can find no explanation for the significantly positive effect of female gender on the first year growth response. Four of the five girls were very young at the start of rhGH treatment, between 1.5 and 2-5 years of age. However, the younger baseline age cannot have influenced the above finding as the multiple regression analysis selects for independent predictors.
For previously treated growth hormone deficient patients, doubling the rhGH dose led to sustained growth improvement. The increment in height SD score for chronological age during three years of study was significantly higher with 4 IU than with 2 IU rhGH.
One of the aims of growth hormone treatment is to normalise statural growth during the growth phase. We therefore investigated how many patients had attained a height SD score above the lower limit of the target range after three years of study, or showed an increase in height SD score above 025 SD scores during year 3, or both. In the transfer group this occurred more frequently for patients on 4 IU rhGH than for those who continued receiving 2 LU/m2/day. For the new patients there was no significant difference in results between doses. The influence of the rhGH dose (2 v 4 IU) being particularly significant for the transfer patients only, may be due to various factors. There was greater severity of growth hormone deficiency in the transfer group, while the chronological age of the transfer patients was significantly more advanced at the start of the study in comparison with the new patients (p=0-018). Another explanation might be that a dose increase rather than the dose as such overcame the waning effect of prolonged rhGH treatment.
After three years of study, one new patient and two transfer patients receiving the higher rhGH dose reached a height SD score for chronological age that surpassed the target height SD score with more than 2 SD scores. For the one new patient the actual height SD score for chronological age was 069 SD scores but for the two transfer patients actual height SD score for chronological age was more than 2 SD scores, that is, above the 97th centile. Although there were no clinical signs or symptoms of acromegaly, 4 IU/m2/day might have been too high a dose for them. For the other transfer patients the higher rhGH dose was clearly beneficial. They all either reached their target range or their height SD score continued to increase substantially, in contrast with just over half the transfers on the lower dose.
The first year increment in height SD score for bone age of new patients was significantly greater with 4 IU than with 2 IU rhGH. However, the increment over a three year period was similar for either dose. Likewise, the three year increment in predicted adult height SD score was comparable for either dose, mean predicted adult height SD score almost reaching target height SD score. This finding may partly be explained by the significantly greater advance in bone maturation with the higher dose during year 3. In the transfer patients, bone maturation was even less with 4 IU than with 2 IU. Mean height SD score for bone age and predicted adult height SD score increased significantly with 4 IU only during three years of study. Since the new patients were younger at the start of the study it might be that the higher rhGH dose has a higher impact on bone maturation of younger than of older growth hormone deficient patients.
For the new patients we could not find a significant correlation between BMI SD score at the start of rhGH treatment and short term or long term growth response. Consequently, our study does not confirm earlier reports that fatter children respond better to growth hormone treatment than relatively thin ones.12 [17] [18] [19] While three years of rhGH treatment had no significant effect on the sitting height/subischial leg length ratio SD score of the growth hormone deficient patients, the results for our transfer patients showed that prolonged growth hormone treatment does lead to a complete normalisation of the upperlower ratio. 26 In our study population, the raised pretreatment cholesterol, LDL and Apo-B concentrations decreased to control values during the three years of rhGH treatment. Although Apo-Al, the major Apo of HDL, showed a tendency to decrease, the concentrations were not below those of controls after three years, irrespective of rhGH dose.
As expected,14 some patients required thyroid medication during rhGH treatment. After three years of study, none of the patients had antigrowth hormone antibodies or any haematological abnormality.
In conclusion: a higher rhGH dose together with a younger age and a lower IGF-I concentration at the start of treatment are significant predictors for the increment in height during the first year of rhGH treatment, but a younger age and a higher difference between height SD score for chronological age and target height SD score are more important for the long term growth response than an rhGH dose of either 2 or 4 IU/m2/day. Therefore, we recommend a dose of 2 IU/m2/day for the first years of rhGH treatment. If the target range has not been reached by then, doubling the dose should be considered. Prolonged treatment with 4 IU rhGH/m2/day appears to be without adverse effects. Careful individualisation of rhGH dosage is indicated as not all growth hormone deficient patients require the higher dose.
